Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Chardan Capital Maintains Buy on Purple Biotech, Maintains $11 Price Target

Author: Benzinga Newsdesk | March 07, 2024 02:56pm
Chardan Capital analyst Daniil Gataulin maintains Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $11 price target.

Posted In: PPBT

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist